• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Research U.K., AstraZeneca sign deal

Cancer Research U.K., AstraZeneca sign deal

January 3, 2014
CenterWatch Staff

Cancer Research U.K. and Cancer Research Technology, the charity's development and commercialization arm, have reached an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.

This is the third agreement the parties have made under the Clinical Development Partnerships (CDP) scheme. CDP is a joint initiative between Cancer Research U.K.'s Drug Development Office (DDO) and Cancer Research Technology (CRT), to develop promising anti-cancer agents which pharmaceutical companies have not selected for further development and CRT is better placed to progress through early phase clinical trials. It is the ninth treatment to enter Cancer Research U.K.'s CDP scheme, with six having progressed into the clinic.

This deal with AstraZeneca will enable the charity's Drug Development Office to complete preclinical development and carry out early clinical trials of the compound to see if it can benefit kidney cancer patients.  Cancer Research U.K.'s DDO also is funding the early phase trial of AZD2098 in which up to 40 patients will take part, set to begin 2015.

AZD2098 targets a molecule found on immune cells called CCR4, which is important for directing these cells to where they need to go. It is thought that in kidney cancer, immune cells move to the tumor because of this molecule. Once the immune cells arrive, the tumor often forces them to become inactive, or worse, help the cancer develop.

By blocking this function, AZD2098 may change the immune cell environment around the cancer, encouraging those cells to attack the tumor. CCR4 also has been found to be expressed on the surface of cancer cells, which may provide an additional way for this blocker to impair tumor growth. The work establishing the potential anti-tumor effect of AZD2098 was carried out by Professor Frances Balkwill at Queen Mary University of London's Barts Cancer Institute and was supported by Cancer Research U.K.

Professor Tom Powles, trial lead and Cancer Research U.K. clinician at Queen Mary University of London, said, "AZD2098 potentially allows us to target the support network which helps keep cancer cells alive, and it may be particularly potent in kidney cancer. As cancer treatments become more and more refined and our ability to attack the disease from new angles increases, we hope to bring forward the day when we can cure this disease."

Around 9,600 people in the U.K. are diagnosed with kidney cancer each year and the incidence rates in Britain have more than doubled since the 1970s.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing